Entrada Therapeutics Inc
TRDA10.630USD
+0.010+0.09%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
406.27MMarket Cap
LossP/E TTM
More Details of Entrada Therapeutics Inc Company
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics Inc Info
Ticker SymbolTRDA
Company nameEntrada Therapeutics Inc
IPO dateOct 29, 2021
CEODoshi (Dipal)
Number of employees183
Security typeOrdinary Share
Fiscal year-endOct 29
AddressOne Design Center Place
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone18573051825
Websitehttps://www.entradatx.com/
Ticker SymbolTRDA
IPO dateOct 29, 2021
CEODoshi (Dipal)
Company Executives of Entrada Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
80.48K
-2.14%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
21.20K
-29.59%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
10.05K
-14.80%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
80.48K
-2.14%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
21.20K
-29.59%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
10.05K
-14.80%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2023Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.95M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
13.20%
MPM Capital Inc.
11.46%
5AM Ventures
10.61%
F. Hoffman La Roche, Ltd.
6.72%
TCG Crossover Management, LLC
5.02%
Other
52.99%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
13.20%
MPM Capital Inc.
11.46%
5AM Ventures
10.61%
F. Hoffman La Roche, Ltd.
6.72%
TCG Crossover Management, LLC
5.02%
Other
52.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
22.93%
Hedge Fund
21.21%
Investment Advisor
18.36%
Corporation
11.27%
Venture Capital
10.99%
Research Firm
2.79%
Private Equity
1.99%
Individual Investor
0.94%
Pension Fund
0.11%
Other
9.41%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
229
29.67M
77.64%
-2.01M
2025Q2
226
35.35M
92.97%
-1.79M
2025Q1
237
37.05M
97.63%
-2.01M
2024Q4
222
37.20M
98.96%
+761.72K
2024Q3
209
35.09M
95.11%
-779.91K
2024Q2
193
34.68M
94.55%
+2.42M
2024Q1
185
31.33M
93.34%
-1.07M
2023Q4
174
31.30M
93.83%
-1.07M
2023Q3
167
31.14M
93.63%
-973.86K
2023Q2
154
30.75M
92.59%
+53.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
4.87M
12.79%
--
--
Jun 30, 2025
MPM Capital Inc.
4.38M
11.52%
--
--
Jun 30, 2025
5AM Ventures
4.26M
11.19%
-52.00K
-1.21%
Jul 09, 2025
F. Hoffman La Roche, Ltd.
2.57M
6.75%
-175.00K
-6.38%
Dec 31, 2024
TCG Crossover Management, LLC
584.96K
1.54%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.81M
4.76%
+80.74K
+4.67%
Jun 30, 2025
Merck & Co Inc
1.74M
4.57%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.60M
4.22%
+32.40K
+2.06%
Jun 30, 2025
Wellington Management Company, LLP
1.06M
2.79%
+7.40K
+0.70%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.6%
iShares Neuroscience and Healthcare ETF
0.26%
iShares Micro-Cap ETF
0.04%
WisdomTree US SmallCap Fund
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.01%
iShares Russell 2000 ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.6%
iShares Neuroscience and Healthcare ETF
Proportion0.26%
iShares Micro-Cap ETF
Proportion0.04%
WisdomTree US SmallCap Fund
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Entrada Therapeutics Inc?
The top five shareholders of Entrada Therapeutics Inc are:
Baker Bros. Advisors LP holds 4.87M shares, accounting for 12.79% of the total shares.
MPM Capital Inc. holds 4.38M shares, accounting for 11.52% of the total shares.
5AM Ventures holds 4.26M shares, accounting for 11.19% of the total shares.
F. Hoffman La Roche, Ltd. holds 2.57M shares, accounting for 6.75% of the total shares.
TCG Crossover Management, LLC holds 584.96K shares, accounting for 1.54% of the total shares.
Baker Bros. Advisors LP holds 4.87M shares, accounting for 12.79% of the total shares.
MPM Capital Inc. holds 4.38M shares, accounting for 11.52% of the total shares.
5AM Ventures holds 4.26M shares, accounting for 11.19% of the total shares.
F. Hoffman La Roche, Ltd. holds 2.57M shares, accounting for 6.75% of the total shares.
TCG Crossover Management, LLC holds 584.96K shares, accounting for 1.54% of the total shares.
What are the top three shareholder types of Entrada Therapeutics Inc?
The top three shareholder types of Entrada Therapeutics Inc are:
Baker Bros. Advisors LP
MPM Capital Inc.
5AM Ventures
Baker Bros. Advisors LP
MPM Capital Inc.
5AM Ventures
How many institutions hold shares of Entrada Therapeutics Inc (TRDA)?
As of 2025Q3, 229 institutions hold shares of Entrada Therapeutics Inc, with a combined market value of approximately 29.67M, accounting for 77.64% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.33%.
What is the biggest source of revenue for Entrada Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Entrada Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
